Evonik to reveal findings from methionine trial at IPPE 2019

Evonik is launching a new White Paper at IPPE in Atlanta addressing the ongoing debate on the relative nutritional value of methionine sources in poultry diets.

The paper ‘Recent broiler trial confirms 2018 EFSA (European Food Safety Authority) scientific opinion on methionine sources while validating the experimental approach’ is by Andreas Lemme and Victor Naranjo, Evonik Nutrition & Care GmbH. It examines different methionine sources under various performance parameters.

As well as reading the White Paper, visitors to IPPE 2019 can try out Evonik Animal Nutrition’s PROXYMet™; a product designed to confirm the superior nutritional value of MetAMINO® versus methionine hydroxy analog free acid (MHA-FA). Using PROXYMet™, customers can now verify the bioefficacy published in numerous studies and trials by themselves.

“Switching to MetAMINO® makes it possible to achieve optimal performance results while realizing substantial savings,” says Alfred Petri, Senior Vice President of Sales Animal Nutrition. “Only 650g of MetAMINO® is required to achieve the same nutritional value as 1,000g MHA-FA. And this is in addition to the other advantages of MetAMINO® – like ease of handling, improved miscibility and shorter batch cycles in feed production.”

People who visit Evonik – in Hall A: Feed Equipment and Animal Feed Ingredients, Booth A2525 – will also learn about the latest version of AMINONIR® Advanced, the company’s new service that analyses unground samples at the point of delivery, as well as AMINORED® 2.0, a new version of Evonik’s service to precisely evaluate soy product quality. Customers will be able to download the new AMINONews App which contains relevant information regarding animal nutrition and health.

About Evonik
Evonik is one of the world leaders in specialty chemicals. The focus on more specialty businesses, customer-orientated innovative prowess and a trustful and performance-oriented corporate culture form the heart of Evonik’s corporate strategy. They are the lever for profitable growth and a sustained increase in the value of the company. Evonik benefits specifically from its customer proximity and leading market positions. Evonik is active in over 100 countries around the world with more than 36,000 employees. In fiscal 2017, the enterprise generated sales of €14.4 billion and an operating profit (adjusted EBITDA) of €2.36 billion.

About Nutrition & Care
The Nutrition & Care segment is led by Evonik Nutrition & Care GmbH and contributes to fulfilling basic human needs. That includes applications for everyday consumer goods as well as animal nutrition and health care. This segment employed about 8,250 employees, and generated sales of around
€4.5 billion in 2017.

Disclaimer
In so far as forecasts or expectations are expressed in this press release or where our statements concern the future, these forecasts, expectations or statements may involve known or unknown risks and uncertainties. Actual results or developments may vary, depending on changes in the operating environment. Neither Evonik Industries AG nor its group companies assume an obligation to update the forecasts, expectations or statements contained in this release.